RE:RE:RE:RE:Melphalen flufenamide
You saying offerings explain the Sp? It all looks rational to you with that info?
I guess I have the sense that people pick some "over-achievers" like cydy (lol) to compare THTX to. There are perfectly good companies, executing well, who have much more down to earth valuations. I'm all for balance.
So at IPO 2017 had a valuation of 200 mil euros, about 200 mil USD at the time. It was ready to start it's Ph2 at the time. As I said the stock quickly rose in the following 18 months or so (tripled, more if you include one of your offerings). We are one stage behind that at the moment. With this as a comparator it's reasonable for THTX's to be valued sub 200 mil now with good prospects for growth on good data.
I'm not against the idea the whole THTX package is grossly undervalued.
scarlet1967 wrote:
Since the IPO this company has been diluting their shares just about every year the total proceeds overall were $455 M!! Balanced view please....
Oncopeptides has completed a directed share issue raising approximately SEK 1,106 million (USD 130 million) Regulatory
March 10, 2021
Oncopeptides has completed a directed share issue raising approximately SEK 1,414 million (USD 144 M)
May 6, 2020 - Regulatory press release
Oncopeptides has completed a directed share issue of approximately SEK 727 million (USD 78 M)
June 28, 2019 - Regulatory press release
Oncopeptides has completed a directed share issue of approximately SEK 546 million
January 24, 2019 - Regulatory press release
Oncopeptides has completed a directed share issue of approximately SEK 314 million
March 22, 2018 - Regulatory press release 38